Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.38 |
| ▸ | MGLL | Q99685 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661192 | 0.88 | LMNA (0.41) | ALDH1A1LMNACYP3A4ALOX15TDP1 | |
| SCHEMBL1889037 | 0.86 | ALDH1A1 (0.38) | ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL14046750 | 0.80 | ALDH1A1 (0.34) | ALDH1A1LMNACYP3A4ALOX15TDP1 | |
| SCHEMBL4968715 | 0.75 | LMNA (0.38) | ALDH1A1LMNACYP3A4ALOX15TDP1 | |
| SCHEMBL9837141 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL1897964 | 0.73 | ALDH1A1 (0.38) | FAAHMGLLALDH1A1LMNAMEN1 | |
| SCHEMBL1891917 | 0.71 | ALDH1A1 (0.43) | ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL11855453 | 0.70 | ALDH1A1 (0.42) | ALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL1886529 | 0.69 | ALDH1A1 (0.35) | ALDH1A1LMNACYP3A4ALOX15TDP1 | |
| SCHEMBL11032438 | 0.68 | ALDH1A1 (0.40) | ALDH1A1CYP3A4ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | disclosed |
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | disclosed |
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | disclosed |
| US-7723286-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2010-05-25 | — | — | US | disclosed |
| US-7723286-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2010-05-25 | — | — | US | disclosed |
| US-7723286-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | disclosed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | disclosed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | disclosed |
| EP-1460994-B1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH & CIE (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-20040220074-A1 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1460994-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003049666-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220074-A1 | Compounds for a controlled release of active molecules | ACLY, PTGES, NOTUM | FAAH 13/4885MGLL 74/4885ALDH1A1 355/4885 |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | ACLY, PTGES, PPOX | FAAH 39/4885MGLL 110/4885ALDH1A1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.